Survodutide

also known as BI 456906

in clinical study incretin metabolicendocrine sequence not characterised

300 heavy atoms · 596 bonds · drag to pan, scroll to zoom C192O61N47

Skeletal structure drawn from the computed atomic coordinates in PubChem CID 171378821. Carbons are implicit vertices; hydrogens on carbon are suppressed, as in any structural formula. Nothing here is estimated — every atom sits where PubChem placed it.

Research reference only. The observations below are recorded in the cited literature. Nothing here is advice or a recommendation, and no dosing information is published on this site.

Sequence

Primary structure not characterised in the public records this index draws on. Nothing is shown rather than something invented.

Dual glucagon/GLP-1 receptor agonist; primary structure not established in openly indexed chemical records at build time.

Molecular data

Chemical fields come from the PubChem compound record; computed values are derived from the sequence shown above.
molecular formula	C192H289N47O61
molecular weight	4232 Da (PubChem)
computed backbone mass	not characterised
length	not characterised
net charge (pH 7.4)	not characterised
mean hydropathy	not characterised
half-life	not characterised
delivery route	subcutaneous
PubChem CID	171378821
PDB	not characterised
UniProt parent	not characterised

Mechanism

Dual agonist at the glucagon and GLP-1 receptors.

Reported targets: GCGR GLP-1R

Experimental structure

No experimental structure of this peptide is deposited in the PDB. Nothing is rendered here — a predicted fold would not be a structure, and this site does not draw one.

Reported effects

Each row is an outcome described in the literature indexed for this peptide. Reported in the cited work — not a claim, not a recommendation.

Reported observations and the corpus they are drawn from.
reported outcome	where it appears
weight loss	Cardiovascular Effects of Glucagon Receptor Signaling Alone and Combined Wit… Journal of the American Heart Association 2026
hepatic fat reduction	Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHR… JACC. Heart failure 2024

Registered trials

Records from ClinicalTrials.gov. Listed for reference — this project sponsors no trial and is not involved in any of them.
NCT	title	status	phase
NCT07221591	A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken u	COMPLETED	PHASE1
NCT06564441	A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine	COMPLETED	PHASE1
NCT07413913	A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formu	COMPLETED	PHASE1
NCT06200467	A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in Peop	COMPLETED	PHASE1
NCT06066528	A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesi	COMPLETED	PHASE3

Literature (8)

Cardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon-Like Peptide-1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus — Journal of the American Heart Association 2026